Muñoz-Corcuera M, Ramírez-Martínez-Acitores L, López-Pintor RM, Casañas-Gil E, Hernández-Vallejo G. Dabigatran: A new oral anticoa-gulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature. Med Oral Patol Oral Cir Bucal. 2016 Nov 1;21 (6):e679-88.

 

doi:10.4317/medoral.21202

http://dx.doi.org/doi:10.4317/medoral.21202

 

 

1. Quintero Gonzalez JA. Fifty years of clinical use of warfarin. Invest Clin. 2010;51:269-87.

 

2. Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, et al. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clin Ther. 2014;36:2015-28.
http://dx.doi.org/10.1016/j.clinthera.2014.09.015

 

3. Nishio H, Ieko M, Nakabayashi T. New therapeutic option for thromboembolism--dabigatran etexilate. Expert Opin Pharmacother. 2008;9:2509-17.
http://dx.doi.org/10.1517/14656566.9.14.2509

 

4. Golembiewski JA. Dabigatran: a new oral anticoagulant. J Perianesth Nurs. 2011;26:420-3.
http://dx.doi.org/10.1016/j.jopan.2011.09.013

 

5. Cohen HV, Quek SY, Subramanian G, Abbas A. New antiplatelet and anticoagulant drugs. Considerations for dental patient management. JNJ Dent Assoc. 2013;84:30-3.

 

6. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e195S-226S.

 

7. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343-8.
http://dx.doi.org/10.1161/CIRCULATIONAHA.111.090464

 

8. Gómez-Moreno G, Aguilar-Salvatierra A, Martín-Piedra MA, Guardia J, Calvo-Guirado JL, Cabrera M, et al. Dabigatran and rivaroxaban, new oral anticoagulants, new approaches in dentistry. J Clin Exp Dent. 2010;2:e1-5.
http://dx.doi.org/10.4317/jced.2.e1

 

9. Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:575-80.
http://dx.doi.org/10.1016/j.oooo.2011.10.006

 

10. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431-41.
http://dx.doi.org/10.1016/j.oooo.2011.10.005

 

11. Davis C, Robertson C, Shivakumar S, Lee M. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 2013;79:74.

 

12. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126:2428-32.
http://dx.doi.org/10.1161/CIRCULATIONAHA.112.123224

 

13. Van Diermen DE, van der Waal I, Hoogstraten J. Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:709-16.
http://dx.doi.org/10.1016/j.oooo.2013.07.026

 

14. Kerr R, Ogden G, Sime G. Anticoagulant guidelines. Br Dent J. 2013;214:430.
http://dx.doi.org/10.1038/sj.bdj.2013.439

 

15. Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:e191-5.
http://dx.doi.org/10.1016/j.oooo.2013.05.001

 

16. Breik O, Cheng A, Sambrook P, Goss A. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J. 2014;59:296-301.
http://dx.doi.org/10.1111/adj.12199

 

17. Curtin C, Hayes JM, Hayes J. Dental Implications of new oral anticoagulants for atrial fibrilacion. Dent Update. 2014;41:526-31.

 

18. Sivolella S, De Biagi M, Brunello G, Berengo M, Pengo V. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. Odontology. 2015;103:258-63.
http://dx.doi.org/10.1007/s10266-015-0195-4

 

19. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27.
http://dx.doi.org/10.1160/TH09-11-0758

 

20. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-60.
http://dx.doi.org/10.1016/j.amjcard.2012.03.049

 

21. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554-62.
http://dx.doi.org/10.1182/blood-2012-11-468207